An evaluation of pemetrexed in second-line treatment of non-small cell lung cancer

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2005-11-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656566.6.16.2855PMID 16318436
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cetuximab in advanced non-small cell lung cancer.

  2006cited by this paper
• Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function.

  2006cited by this paper
• Novel Agents in the Treatment of Lung Cancer

  2006cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer

  2006cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• A phase I dose-escalating study of combination pemetrexed-based chemotherapy and concomitant radiotherapy for locally advanced or metastatic non-small cell lung or esophageal cancer

  2005cited by this paper
• A phase II study of erlotinib as first-line treatment of advanced non-small cell lung cancer.

  2005cited by this paper
• PD-068 An exploratory analysis of a phase III study in patients with advanced non-small cell lung cancer (NSCLC): The impact of first-line gemcitabine and platinum therapy on the outcome of second-line therapy with pemetrexed or docetaxel

  2005cited by this paper
• Results from a phase II, open-label, randomized study (SIGN) comparing gefitinib with docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

  2005cited by this paper
• Phenotypic heterogeneity in multiple myeloma families.

  2005cited by this paper
• Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial.

  2005cited by this paper
• Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.

  2005cited by this paper
• A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer.

  2005influential reference
• The evolving role of pemetrexed (Alimta) in lung cancer.

  2005influential reference
• The ALPI Trial: The Italian/European Experience with Adjuvant Chemotherapy in Resectable Non–Small Lung Cancer

  2005cited by this paper
• Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.

  2005cited by this paper
• TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

  2005cited by this paper
• Erlotinib in lung cancer - molecular and clinical predictors of outcome.

  2005cited by this paper
• 486 A phase I study of pemetrexed supplemented with folic acid (FA) and vitamin b12 (VB12) in Japanese patients with solid tumors

  2004cited by this paper
• A phase II trial of pemetrexed (P) plus carboplatin (C) in patients (pts) with advanced non-small-cell lung cancer (NSCLC).

  2004cited by this paper
• Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

  2004cited by this paper
• Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

  2004cited by this paper
• Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

  2004influential reference
• Cetuximab in Advanced Non-Small Cell Lung Cancer

  2004cited by this paper
• Novel agents in the treatment of lung cancer: conference summary statement.

  2004cited by this paper
• Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC).

  2004cited by this paper
• American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

  2004cited by this paper
• Post study docetaxel in non-small cell lung cancer (NSCLC) patients after discontinuation from a randomized phase III trial of pemetrexed versus docetaxel: An exploratory analysis.

  2004cited by this paper
• Interstitial lung disease associated with drug therapy

  2004cited by this paper
• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  2003cited by this paper
• Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

  2003cited by this paper
• Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.

  2003cited by this paper
• ALIMTA (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study.

  2003cited by this paper
• Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma.

  2003cited by this paper
• Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.

  2003cited by this paper
• O-5 Multiple regression analysis of prognostic variables for survival from the phase III study of pemetrexed versus docetaxel in non-small-cell lung cancer (NSCLC)

  2003cited by this paper
• PL-5 A phase III study of pemetrexed vs. docetaxel in patients with advanced non-small-cell lung cancer (NSCLC) who were previously treated with chemotherapy

  2003cited by this paper
• Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer.

  2002cited by this paper
• Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

  2002cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002cited by this paper
• Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy.

  2002cited by this paper
• Global and regional estimates of cancer mortality and incidence by site: II. results for the global burden of disease 2000

  2002cited by this paper
• Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first‐line therapy in patients with advanced nonsmall cell lung carcinoma

  2001cited by this paper
• Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors.

  2001cited by this paper
• Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck

  2001cited by this paper
• ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC).

  2001cited by this paper
• Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.

  2001cited by this paper
• Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis.

  2001cited by this paper
• Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma

  2000cited by this paper
• Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer.

  2000cited by this paper
• Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial.

  2000cited by this paper
• The mechanism of transport of the multitargeted antifolate (MTA) and its cross-resistance pattern in cells with markedly impaired transport of methotrexate.

  2000cited by this paper
• A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation

  1999cited by this paper
• Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group.

  1999cited by this paper
• Overview of phase I trials of multitargeted antifolate (MTA, LY231514).

  1999cited by this paper
• Enzyme inhibition, polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis.

  1999cited by this paper
• Overview of phase II trials of MTA in solid tumors.

  1999cited by this paper
• Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514.

  1999cited by this paper
• Antifolates: the next millennium.

  1999cited by this paper
• Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRF-CEM cells.

  1998cited by this paper
• Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA).

  1998influential reference
• LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.

  1997cited by this paper
• A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5- yl)ethyl]benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase.

  1992cited by this paper

• A retrospective study of pemetrexed combined with oxaliplatin as second‐line treatment for advanced non‐small‐cell lung cancer: Comparable toxicity, better outcome

  2011cites this paper
• Clinical predictive factors for advanced non-small cell lung cancer (NSCLC) patients receiving third-line therapy: Selecting the unselectable?

  2010cites this paper
• No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data.

  2009cites this paper
• Cancer treatments: can we find treasures at the bottom of the sea?

  2009cites this paper
• Vitamin B12-mediated transport: a potential tool for tumor targeting of antineoplastic drugs and imaging agents.

  2008cites this paper
• Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.

  2008cites this paper
• Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?

  2008cites this paper
• Maintenance therapy with gefitinib after first-line chemotherapy in patients affected by advanced non-small cell lung cancer.

  2007cites this paper
• Cyanocobalamin (vitamin B12) conjugates with enhanced solubility.

  2007cites this paper